DSpace Repository

From randomized clinical trials (RCTS) to artificial intelligence (AI) – history and methodological challenges

Show simple item record

dc.contributor.author ANTES, Gerd
dc.date.accessioned 2024-04-24T09:38:37Z
dc.date.available 2024-04-24T09:38:37Z
dc.date.issued 2024
dc.identifier.citation ANTES, Gerd. From randomized clinical trials (RCTS) to artificial intelligence (AI) – history and methodological challenges. In: Quo Vadis – Ethics of the Scientific Research: conf. NANO-2024, event devoted to the 60th anniversary of the Technical University of Moldova, 15-18 April 2024, Chişinău, Republica Moldova: Program and proceedings of the conference, Chişinău 2024, pp. 40-41. ISBN 978-9975-64-422-8. en_US
dc.identifier.isbn 978-9975-64-422-8
dc.identifier.uri http://repository.utm.md/handle/5014/26871
dc.description.abstract From 1991 to 2020 a considerable number of quality devices (i. e. Equator [2] have been developed and implemented, for the quality of all steps of trials from planning to implementing the knowledge derived from results. This may sound as if it was an easy path but it was not. Quality is a value which is under permanent attack and has to be defended. Bias is a major aggressor, probably the most famous in that camp is the publication bias. Up to 50% of research results are not published, with a heavy bias of what is published and visible [3], accordingly with serious ethical impact [4]. In recent years a new era has been launched, starting 2008 with a provocative article claiming that enough data make the scientific method obsolete [5]. Big Data, artificial intelligence (AI) and personalized medicine (also called precision medicine) have generated a realm of visions and promises where the quality issue seems to have completely disappeared: Unlimited data guarantee any level of needed quality, without particular effort. Can this be expected, or where is the border between realistic expectations and marketing-driven promotion? We are observing a confrontation and a cultural clash between the “old”, methods-driven world and the new “informatics-based” or “data-driven” world which is not receiving the attention it deserves in the current climate of enthusiasm and hype [6]. It is urgent to avoid misleading perspectives and return to strictly quality-driven research agendas and the implementation of these methods [7]. The presentation describes and illustrates these different methods worlds and their tensions and controversies. en_US
dc.language.iso en en_US
dc.publisher Technical University of Moldova en_US
dc.relation.ispartofseries NANO-2024 "Quo Vadis – Ethics of the Scientific Research", event devoted to the 60th anniversary of the Technical University of Moldova;15-18 April 2024, Chişinău, Republica Moldova
dc.rights Attribution-NonCommercial-NoDerivs 3.0 United States *
dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/3.0/us/ *
dc.subject randomization procedure en_US
dc.subject clinical trials en_US
dc.subject Health services en_US
dc.title From randomized clinical trials (RCTS) to artificial intelligence (AI) – history and methodological challenges en_US
dc.type Article en_US


Files in this item

The following license files are associated with this item:

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 United States Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 United States

Search DSpace


Advanced Search

Browse

My Account